81675 München, de
+49 (89) 413138-29
WILEX successfully completes Phase II study with RENCAREX®* in combination with Interferon
RENCAREX® in combination with low dose Interferon alpha-2a leads to a 2 year survival rate of 57 % for patients with progressive metastatic renal cell cancer
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to firstname.lastname@example.org.